CT
BPMC

Clearstead Trust’s Blueprint Medicines BPMC Stock Holding History

Clearstead Trust’s Portfolio BPMC Stock Details BPMC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-101
Closed -$12.9K – 1520
2025
Q2 		$12.9K Hold
101
– – ﹤0.01% 525
2025
Q1 		$8.94K Hold
101
– – ﹤0.01% 490
2024
Q4 		$8.81K Hold
101
– – ﹤0.01% 366
2024
Q3 		$9.34K Hold
101
– – ﹤0.01% 348
2024
Q2 		$10.9K Hold
101
– – ﹤0.01% 352
2024
Q1 		$9.58K Hold
101
– – ﹤0.01% 353
2023
Q4 		$9.32K Hold
101
– – ﹤0.01% 339
2023
Q3 		$5.07K Hold
101
– – ﹤0.01% 382
2023
Q2 		$4.54K Hold
101
– – ﹤0.01% 336
2023
Q1 		$4.54K Hold
101
– – ﹤0.01% 321
2022
Q4 		$4K Hold
101
– – ﹤0.01% 342
2022
Q3 		$7K Hold
101
– – ﹤0.01% 304
2022
Q2 		$5K Sell
101
-251
-71% -$14.7K ﹤0.01% 161
2022
Q1 		$22K Sell
352
-165
-32% -$11.8K 0.01% 137
2021
Q4 		$55K Hold
517
– – 0.03% 128
2021
Q3 		$53K Buy
+517
New +$48.1K 0.03% 131

Other funds holding BPMC

DekaBank Deutsche Girozentrale
DekaBank Deutsche Girozentrale Frankfurt, Germany $60.6B AUM 23.27% 1-Year Est. Return
VanEck Associates
VanEck Associates New York $133B AUM 72.99% 1-Year Est. Return
IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return
Osaic Holdings
Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return
HNB
Huntington National Bank Columbus, Ohio $18.1B AUM 24.69% 1-Year Est. Return

Clearstead Trust's BPMC Position: Q3 2025 in Review

Clearstead Trust sold out of Blueprint Medicines (BPMC) in Q3 2025, closing a stake of 101 shares — an estimated $12.9K sold.

Clearstead Trust first reported a position in BPMC in Q3 2021 and held it in 16 quarters. The position peaked at $55K in Q4 2021. 5 funds tracked by Wall St. Rank hold BPMC as of Q3 2025.

  • Clearstead Trust reported no remaining Blueprint Medicines position as of Q3 2025 after selling out during the quarter.
  • Clearstead Trust sold 101 Blueprint Medicines shares in Q3 2025, an estimated $12.9K.
  • Clearstead Trust first reported a position in Blueprint Medicines in Q3 2021 and held it in 16 quarters.
  • Clearstead Trust's Blueprint Medicines position peaked at $55K in Q4 2021.
  • 5 funds tracked by Wall St. Rank held Blueprint Medicines as of Q3 2025.

Based on Clearstead Trust's 13F filing for Q3 2025, filed 10 Nov 2025.